These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 1746070)

  • 21. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate cancer: metastatic.
    Michaelson MD; Talcott JA; Smith MR
    Clin Evid; 2002 Dec; (8):881-90. PubMed ID: 12603918
    [No Abstract]   [Full Text] [Related]  

  • 23. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone.
    Scholz M; Jennrich R; Strum S; Brosman S; Johnson H; Lam R
    J Urol; 2005 Jun; 173(6):1947-52. PubMed ID: 15879788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
    Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
    Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide).
    Isurugi K; Niijima T; Akaza H; Aso Y; Koiso K; Fuse M; Okada K; Usami M; Ohashi T; Ueda T;
    J Chemother; 1989 Jul; 1(4 Suppl):1237-41. PubMed ID: 16312848
    [No Abstract]   [Full Text] [Related]  

  • 26. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
    Williams G; Lindsay S; Bowsher WG
    Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical evaluation of enantone in the treatment of prostate cancer].
    Zhang L; Tao D; Wang S
    Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):218-20. PubMed ID: 10920902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
    Curry EA; Sweeney CJ
    J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment of uterine leiomyoma with depot leuprorelin acetate (Enantone-Gyn monthly depot). Effect on leiomyoma volume and operability. German Leuprorelin Study Group].
    Stolz W; Pfützenreuter N
    Zentralbl Gynakol; 1997; 119(10):468-75. PubMed ID: 9432825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overview of hormonal therapy for prostate cancer.
    Carter HB; Isaacs JT
    Prog Clin Biol Res; 1990; 350():129-40. PubMed ID: 2201039
    [No Abstract]   [Full Text] [Related]  

  • 31. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup.
    Garzotto M; Wajsman Z
    J Urol; 1998 Mar; 159(3):950-4; discussion 954-5. PubMed ID: 9474190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hormone chemotherapy for newly diagnosed patients with metastatic prostate cancer.
    Kubota Y; Nakada T; Suzuki Y; Iizima Y; Adachi Y; Hashimoto T
    Int Urol Nephrol; 1993; 25(5):469-74. PubMed ID: 8270375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K; Akaza H; Naito S; Usami M; Tsukamoto T; Shimazaki J; Kotake T; Yamanaka H; Oohashi Y; Yoshinaka R; Onouchi H; Yokokawa K
    Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].
    Imai K; Kumasaka F; Kobayashi M; Suzuki T; Takahashi O; Yamanaka H
    Hinyokika Kiyo; 1985 Dec; 31(12):2302-6. PubMed ID: 2938456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delayed hormonal therapy in advanced prostatic cancer.
    Zungri E; Salvador J; Chéchile G; Diaz I; Martinez E
    Prog Clin Biol Res; 1987; 243B():441-7. PubMed ID: 3659038
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K
    Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined androgen blockade: leuprolide and flutamide versus leuprolide and placebo.
    Crawford ED; Goodman P; Blumenstein B
    Semin Urol; 1990 Aug; 8(3):154-8. PubMed ID: 2119048
    [No Abstract]   [Full Text] [Related]  

  • 38. [Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
    Taguchi T; Koyama H; Yayoi K; Wada T; Takatsuka Y; Sonoo H; Morimoto K; Tominaga T; Abe R; Enomoto K
    Gan To Kagaku Ryoho; 1995 Mar; 22(4):495-508. PubMed ID: 7887641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hormonal treatment of advanced disease: some newer aspects.
    Griffiths K; Eaton CL; Harper ME; Turkes A; Peeling WB
    Semin Oncol; 1994 Oct; 21(5):672-87. PubMed ID: 7939755
    [No Abstract]   [Full Text] [Related]  

  • 40. Monitoring of prostate volume by ultrasound in hormonally treated prostate cancer.
    Brandt B; Menu G; el Khansa A; Lardennois B
    Prog Clin Biol Res; 1987; 243B():13-9. PubMed ID: 3309979
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.